Ipamorelin vs Kisspeptin-10
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue (GHS) and ghrelin receptor agonist. It stimulates GH release with high selectivity — minimal cortisol or prolactin elevation compared to older GHRPs. Widely used in research protocols for body composition, sleep quality, and recovery.
Full profileKisspeptin-10
Kisspeptin-10 is the biologically active 10-amino acid C-terminal fragment of kisspeptin, a neuropeptide that acts as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. By activating KISS1R (GPR54) in the hypothalamus, it triggers pulsatile GnRH release, which drives LH, FSH, and downstream testosterone and estrogen production. It is the upstream signal that 'turns on' the reproductive axis — with research applications spanning fertility, hypogonadism, post-cycle therapy support, and age-related hormonal decline.
Full profile| Ipamorelin | Kisspeptin-10 | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | NNC 26-0161, Ipamorelin acetate | KP-10, Metastin(112-121), KISS1R agonist |
| Evidence | Investigational (in trials) | FDA-approved |
| Dosing range | 100mcg–300mcg mcg, 1–3x daily (typically pre-sleep and/or pre-workout) | 50mcg–250mcg mcg, 1–2x daily (pulsatile administration is important — avoid continuous infusion) |
| Administration | Subcutaneous injection, Intramuscular injection | Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses) |
| Key side effects | Water retention (mild), Tingling / numbness in extremities, Increased appetite, Headache (transient) | Generally well-tolerated in clinical trials, Nausea (mild, uncommon), Potential for over-stimulation of the HPG axis at high doses (rarely significant), Theoretical desensitization with continuous (non-pulsatile) dosing |
| Cited sources | 3 references | 3 references |
Key differences
- Evidence level differs: Ipamorelin is investigational (in trials), while Kisspeptin-10 is fda-approved.
- Administration: Ipamorelin — Subcutaneous injection, Intramuscular injection; Kisspeptin-10 — Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses).
- Frequency: Ipamorelin is typically 1–3x daily (typically pre-sleep and/or pre-workout); Kisspeptin-10 is 1–2x daily (pulsatile administration is important — avoid continuous infusion).
How each works
Ipamorelin
Ipamorelin selectively stimulates GH release via the ghrelin receptor (GHS-R1a) without significantly elevating ACTH or cortisol — the feature that distinguishes it from GHRP-6 and GHRP-2 (Raun et al., 1998, in swine/rodent models). Human data are limited: a PK study in 40 volunteers established a ~2-hour half-life (Gobburu et al., 1999), and a Phase 2 trial for postoperative ileus (Beck et al., 2014) failed its primary endpoint. It is not FDA-approved, and claims about body composition or recovery are extrapolated from GH physiology, not human outcome trials.
Kisspeptin-10
Kisspeptin neurons in the arcuate nucleus form the pulse generator for GnRH secretion — without kisspeptin signaling, reproductive function ceases. Human clinical trials confirm that IV kisspeptin-10 produces rapid, dose-dependent LH pulses in both males and females, restoring hormonal function in hypogonadotropic hypogonadism. Kisspeptin-54 (the longer form) has been studied in human fertility treatments with successful outcomes. Unlike direct LH/FSH administration, kisspeptin works upstream at the hypothalamus, preserving the natural pulsatile release pattern and avoiding receptor desensitization associated with continuous GnRH agonists.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.